As a Network Lead Participating Site, the Stanford Cancer Institute (SCI) will provide overall leadership to ensure the collaboration and success of the U10 leadership team and of individual investigators who are active in enrolling patients onto cooperative group studies as participants in the NCTN. Stanford has a long history of active participation across multiple NCTN cooperative groups as evidenced by a strong publication lists and clinical trial enrollment. With this history and with the strong support from SCI leadership, a well-functioning and centralized CCTO, strong basic science and translational medicine, and increasing support for clinical research from Stanford Hospitals and Clinics, Stanford investigators are poised to continue their leadership and markedly enhance accrual to cooperative group studies in the NCTN.

Public Health Relevance

The translation of scientific ideas into therapies that bring new hope to cancer patients is a central aspect of the Stanford Cancer Institute's and mission and those of other NCI-designated cancer centers. SCI's Participation as a Lead Academic Participating Site in the NCTN will create critical synergies that will help fulfills that mission t NCTN, SCI and other cancer centers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA180816-01
Application #
8605353
Study Section
Special Emphasis Panel (ZCA1-GRB-P (O1))
Program Officer
Mooney, Margaret M
Project Start
2014-06-19
Project End
2019-02-28
Budget Start
2014-06-19
Budget End
2015-02-28
Support Year
1
Fiscal Year
2014
Total Cost
$576,471
Indirect Cost
$217,299
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Press, Oliver W; Li, Hongli; Schöder, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7
Baljevic, Muhamed; Dumitriu, Bogdan; Lee, Ju-Whei et al. (2016) Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia. Acta Haematol 136:210-218
Kenkre, Vaishalee P; Hong, Fangxin; Cerhan, James R et al. (2016) Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clin Cancer Res 22:821-6
Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7
Diefenbach, Catherine S; Li, Hailun; Hong, Fangxin et al. (2015) Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530-8
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2015) Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 373:2005-14
Swinnen, Lode J; Li, Hailun; Quon, Andrew et al. (2015) Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404). Br J Haematol 170:56-65
Schneider, Bryan P; Li, Lang; Radovich, Milan et al. (2015) Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. Clin Cancer Res 21:5082-91

Showing the most recent 10 out of 13 publications